Brigatinib is marketed under the brand name Alunbrig [1].
What is Alunbrig used for?
Alunbrig is a prescription medication used to treat adults with anaplastic lymphoma kinase-positive (ALK-positive) metastatic non-small cell lung cancer (NSCLC) who have not been treated with an ALK inhibitor previously, or whose disease has worsened after treatment with crizotinib [1].
How does Alunbrig work?
Brigatinib is a tyrosine kinase inhibitor (TKI). It works by blocking the action of an abnormal protein called ALK, which can cause cancer cells to grow and multiply. By inhibiting ALK, brigatinib helps to slow or stop the growth of cancer cells [1].
When does Alunbrig's patent expire?
Patent information for Alunbrig can be tracked through resources like DrugPatentWatch.com [2]. Specific patent expiry dates depend on various factors, including the type of patent (e.g., composition of matter, method of use) and any granted extensions.
Who makes Alunbrig?
Alunbrig is manufactured by Takeda Pharmaceutical Company [1].
What are the side effects of Alunbrig?
Common side effects of Alunbrig can include diarrhea, nausea, fatigue, cough, headache, and rash [1]. More serious side effects may include lung problems, high blood pressure, liver problems, and vision changes [1]. Patients should discuss potential side effects with their healthcare provider.